Find information on thousands of medical conditions and prescription drugs.

Aciphex

Rabeprazole is a proton pump inhibitor sold (as its sodium salt) under the brand name Aciphex and Pariet (distributed by Janssen-Ortho).

It is used in the treatment of gastric ulcers and GERD (or heartburn). It is taken once/day along with a full glass of water (preferable 30 min before breakfast). The duration of treatment is usually 4 weeks but could be longer if the symptoms persist.

Sometimes, one may start feeling better after a few days but it is essential to complete the full course of treatment.

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


High cost of drugs has little to do with innovation
From Healthfacts, 10/1/04

For older folks enrolled in Medicare (and this writer is one) the news of late has been mostly bad. For example, Medicare's trustees estimate that out of pocket expenses for Medicare premiums, deductibles and co-pays will consume more than a third of our Social Security income by 2006. I include as bad news the prescription drug benefit that Congress enacted last year. What I find most disturbing is that the new law forbids government from using its clout to negotiate lower prices--guaranteeing that drug price inflation will continue for the foreseeable future.

The drug industry staunchly defends high prices as essential to fund critical drug research and development. Industry apologists point to treatments for life-threatening conditions like cancer, HIV and heart disease that were not around a few decades ago as justification for banning government from price bargaining. Reining in profits, we are warned, would cause investor dollars needed for research to dry up, and we would be denied future life-saving therapies. Policy makers appear easily swayed by this argument. What elected official wants to be portrayed as blocking research that may produce a life-saving treatment?

How valid is the drug industry's claim that high profits are necessary to support medical progress? In his new book, The $800 Million Dollar Pill, Merrill Goozner sets out to provide some answers. The title refers to what drug manufacturers claim it costs them to get a new drug approved by the FDA--an estimate that is considerably exaggerated.

Goozner, a former Chicago Times economic correspondent, provides a detailed history of the scientific and commercial development of a number of specific drug and biotech products to treat life-threatening illnesses. In the final analysis, he argues, private drug industry investment has not been the most important factor in the discovery and development of important new therapies. In fact, Goozner argues, the success of the drug industry in developing new, life-saving treatments has been largely dependent on government sponsored research and researchers. The result is that American taxpayers end up paying twice: first through their tax dollar support of the National Institutes of Health and of academic research--and then again by paying high prices when they need the drugs. Goozner also discusses the wasteful economics of "me too" or "copy-cat" drugs. By definition, they offer no advantage but are different enough to secure a patent. Goozner traces the industry's love affair with me-too products back to the 1940s.

The industry's copy cat fervor continues unabated today while at the same time the number of newly approved innovative drugs has fallen sharply. According to the FDA's web site, only 21 out of 72 new drug approvals in 2003 were "innovator" drugs with an active ingredient new to the U.S. market. Of those 21, less than half were considered by the FDA to be a significant improvement compared to already marketed products. An editorial in The Lancet (9/24/04) aptly describes this current state of affairs: "In last-ditch flings at seeking new markets, the drugs industry can only come up with new indications for old drugs and me-too compounds to barge into existing markets." The popular heartburn drug, Nexium, for example, is just an expensive knockoff of Prilosec, Prevacid, Protonix and Aciphex.

Drug makers spend tens of billions of dollars to aggressively promote their me-too products and expand market share. In addition, as Goozner argues, and the FDA's judgment above confirms, the largest slice of the research and development dollars spent by industry produces therapies that provide no therapeutic advantage to patients. To add insult to injury, the market share competition among me-too drugs does not necessarily mean lower prices; in fact many are priced higher than the "innovator" drug.

President Bush touts his "marketplace" approach to solving our health care problems on the campaign trail. But nothing is more anti-marketplace than not allowing Medicare to use its buying power to negotiate lower prices for drugs. It's time, I would argue, for policy makers to be more questioning about drug industry claims that lower drug prices will stifle innovation and hurt the sick. After all, The $800 million Pill provides convincing evidence that industry's appetite for high profits is mostly self-serving.

COPYRIGHT 2004 Center for Medical Consumers, Inc.
COPYRIGHT 2004 Gale Group

Return to Aciphex
Home Contact Resources Exchange Links ebay